BioMed Nexus

📈 The Divergence: Why Kodiak Soared (+12%) vs. Immunome Sank

Biotech Financing Returns (Selectively) | 📉 Pfizer's "Value Trap" | 💊 A "Bankrupt" Drug Wins

🟢 GSK Wins. 🔴 Aldeyra Delays. 🧟 XOMA's "Zombie" Play.

📉 Pfizer Falls -5% | 💰 Sobi's $950M Bet | ⚠️ The "Holiday" Binaries

🟢 Enhertu Approved. 🔴 Aldeyra Delayed. 🏆 Roche Wins.

The Full SABCS Debrief | 📉 Sanofi's Phase 3 Miss | ⚠️ Binary Risks Shift

Innoviva Approved + Aldeyra's Final Verdict

⚠️ The Week Ahead (ALDX) | 🏆 BioCryst & Innoviva Wins | 📉 Recursion's Fade

Google Enters the Clinic + BioCryst Decision Day

🔴 Regulatory Verdicts Today | 🧪 Isomorphic's First Trial | 🤖 Medra's $52M Robots

PDUFA Watch: BioCryst & Amgen Decisions + Post-CPI Rally

⚠️ Regulatory Verdicts Tomorrow | 📈 Structure Analyst Upgrades | 🧪 Kelonia's "In Vivo" Win

📊 Chart of the Week: The "Obesity Gap" + Pfizer's New $2B Bet

Syndax Rallies | Incyte's Lymphoma Win | CPI Volatility Ahead

🚀 Obesity Shock: Wave (+147%) & Structure (+102%) Redefine the Market

Terns Challenges Novartis | Dyne's DMD Win | $750M in New Raises

🩸 ASH Shock: Vertex & Arcellx Win + The Oral GLP-1 Verdict (Today)

Structure Data Imminent | Capricor's 371% Week | Dyne's DMD Readout

🧪 Deal Rush: SciNeuro's $53M Win + The ASH 2025 Preview

Capricor Target Raised to $60 | Intuitive Shares Slide | ImPact’s Urology Win

The 500% Gainer: Capricor’s Win + Medtronic’s Robot War

BMS Stumbles | BioCryst Deal Clears | The New "Data Premium" Trade

⚠️ FDA Shock: Pazdur Out + The $150M Gene Writing Bet

Tariffs hit 0% | Otsuka's Renal Win | Small Cap PRV is Back

0% Pharma Tariffs, Exact’s ~$21B Exit, and FDA’s Vaccine Shift — BioMed Nexus Daily

U.S.–U.K. lock in 0% medicine tariffs, Abbott acquires Exact Sciences for ~$21B, FDA tightens vaccine approvals, and Otsuka wins a kidney nod — as regulatory tolerance meaningfully narrows.

Diagnostics Pivot, Gene-Therapy Expansion & CGM Safety Shock

A pivotal week spanning Itvisma’s expanded SMA label, Abbott’s 3M-unit Libre 3 correction, global CAR-T momentum, a $23B diagnostics megadeal, and strengthening signals in biomimetics and 505(b)(2) oncology strategies

Global CAR-T Approval, 505(b)(2) Oncology Deal, and Biomimetics Surge

Light U.S. flow on the holiday, but global oncology, biomimetics, and device-quality signals delivered real clues for next week.

Abbott’s Libre Safety Shock + Itvisma’s Gene-Therapy Expansion

Itvisma becomes the first gene-replacement therapy for SMA patients 2+ years old, Abbott confronts a global CGM accuracy correction, and neuromuscular and device-safety frameworks shift heading into the holiday break.

Libre 3 Safety Shock, Gene-Therapy Expansion, ADC Deals, and CGM Drift Scrutiny

Global Libre 3 correction deepens, Novartis expands SMA therapy, CytomX inks new ADC deal, and FDA attention shifts toward CGM drift performance.

Libre 3 Alert: Global Correction + Novartis’ SMA Breakthrough

Libre 3 correction hits 3M units globally (736 AEs, 7 deaths); Novartis expands SMA gene therapy to older children.

Diagnostics Surge: Abbott’s $23B Bid, Two Precision Oncology Wins, and AI Infra Momentum

Abbott’s $23B Exact Sciences buy, two FDA precision-oncology wins, and AI-bio infrastructure shifts define the week.

Abbott’s $23B Diagnostics Play, HER2 Lung Win, NF1 Expansion

Abbott acquires Exact Sciences in a landmark $23 billion deal, FDA approves sevabertinib for HER2-mutated NSCLC and expands selumetinib to adult NF1, while diagnostics, AI-bio and device convergence...

HER2 Lung Cancer Win, NF1 Expansion, Retina Dosing Flexibility, and Medtech AI Momentum

FDA expands tools in HER2-mutated lung cancer and NF1; aflibercept gains new dosing flexibility; AI-biotech surges; insulin tech, vascular devices, and imaging IPO plans shape corporate flow.

Redemplo’s RNAi Approval, Medtronic’s Device Surge, And GLP-1 Price Pivots

FDA greenlights Arrowhead’s RNAi for ultra-rare FCS, expands epcoritamab in lymphoma, Medtronic’s heart devices turbocharge guidance, and GLP-1 pricing plus telehealth deals redraw the obesity map.

Halda’s $3B Oncology Buyout, First Perjeta Biosimilar, Pivotal ALK Data, and NIH Trial Shock

A $3B oncology deal, the first interchangeable Perjeta biosimilar, breakthrough ALK data, and a federal research disruption affecting 74,000 trial participants.

Obesity Wars, Flu Megadeals, Gene Therapy Shock: Your Week In BioPharma And MedTech

From Pfizer’s obesity win and Merck’s $9.2B flu bet to an FDA gene therapy clampdown and $200M surgical robotics financing, this week’s moves reset risk and capital across biotech, medtech, and pharma.

FDA’s New Ultra-Rare Pathway, Healthineers Shake-Up, Editing Platform Cuts, and Global Rotation Signals

The FDA opens a new path for ultra-rare therapies, Siemens reshapes Healthineers, Korro and Metagenomi retrench, medtech prints strength, and real-time capital flows shift toward tools and immunology.